Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre,...

Area of Science:

• Neurology
• Psychiatry
• Clinical Pharmacology

Background:

• Comorbid depressive symptoms in restless legs syndrome (RLS) present a treatment challenge.
• Some antidepressants can worsen RLS symptoms, necessitating alternative therapeutic approaches.
• Preliminary evidence suggests ropinirole may possess antidepressant properties.

Purpose of the Study:

• To investigate the efficacy of ropinirole immediate release (IR) in treating depressive symptoms in patients with moderate to severe idiopathic RLS.
• To assess the impact of ropinirole IR on RLS severity.
• To determine the optimal treatment sequence for patients with comorbid RLS and depression.

Main Methods:

• A multicenter, placebo-controlled, double-blind randomized study.
• 231 patients with moderate to severe idiopathic RLS and mild depressive symptoms were included.
• Ropinirole IR (up to 4 mg/day) or placebo was administered for 12 weeks.

Main Results:

• Ropinirole IR significantly reduced Montgomery-Asberg Depression Rating Scale (MADRS) scores compared to placebo (P < 0.001).
• Ropinirole IR also showed superiority in improving depression scores on the Hamilton Scale for Depression and Beck Depression Inventory-II.
• RLS severity scores (IRLS) significantly decreased with ropinirole compared to placebo (P < 0.001), with improvements in sleep quality.

Conclusions:

• Ropinirole IR is effective in treating comorbid depressive symptoms in patients with moderate to severe RLS.
• Treatment of RLS symptoms should be prioritized, as this may alleviate associated depressive symptoms.
• Antidepressant medication may be considered if depressive symptoms persist after adequate RLS treatment.